Louis Garguilo
ARTICLES BY LOUIS
-
5/21/2020
Inspiration and "circle economics" could help shape your outsourcing decisions. And who knows: It all might end up supporting a more robust national drug-manufacturing infrastructure.
-
5/15/2020
The Wuhan coronavirus outbreak has brokered a virulent "value" chain debate around the world, including a global CDMO's CEO situated in Tokyo.
-
5/14/2020
Pfizer’s speaking in real-time – actually forward-looking pronouncements of manufacturing intentions and locations – is refreshing, and should be applauded. Does this represent an industry "shift"?
-
5/11/2020
The CDMO market is estimated to grow to $157.7 billion in 2025, a compound annual growth rate (CAGR) of 6.9%, according to an industry report. But what kind of CDMO growth is best for Outsourced Pharma readers?
-
5/6/2020
To diversify China-dependent supply chains and procure materials, API and products in the U.S., we'd literally need to start digging.
-
5/1/2020
Don Buckner left a comment to my recent '50 By 25" editorial: “Will have success if the buyers demand it.” I liked the idea of buyer-driven demand as a path to explore your supply-chain decisions. It also led to some fundamental questions of your motivations.
-
4/27/2020
That’s an unwieldy title for an editorial. But we’ll bundle those three components quickly, thanks to U.S.-based GeoVax Labs CEO David Dodd. He's the quintessential professional to assist readers in assessing and contemplating current and future realities.
-
4/20/2020
The questions James E. Brown, President & CEO, DURECT, asked of CDMOs when he founded the company in 1998 remain perfectly operational: "Who are they? Where did those individuals come from? What are their personal track records?”
-
4/16/2020
At this time of difficult political, economic, and health-related decision-making, the entire nation needs your practiced mix of data centrality, and your experience in partnerships and (supply-chain) systems where qualitative analysis also play a major role.
-
4/15/2020
We featured Sara McCutchan in an earlier editorial, "A Path To Biotech For Young Women." Here she provides strong examples and best practices for small biotechs reliant on outsourcing drug development to CDMOs.